FDA Brief

Warning letters Drugs

FDA warning letter to

Oasis Medical, Inc.

High riskIssued Jul 15, 2025Posted Aug 5, 2025Center for Drug Evaluation and Research (CDER)

FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

What happened

FDA inspected Oasis Medical's drug manufacturing facility in Glendora, CA, from January 15 to 27, 2025. FDA found inadequate process controls for sterile ophthalmic products, excessive rejected units due to visible particulates, and batches with high defect levels were distributed. FDA also found inadequate investigations of sterility and bioburden failures, inadequate finished-product and stability testing, and insufficient quality unit oversight.

What FDA found

  1. The company lacked adequate written production and process controls for sterile ophthalmic drugs, its process produced excessive defective units with visible particulates, and batches with high defect levels were distributed.

    21 CFR 211.100(a)
  2. The company did not adequately investigate a failed sterility test or bioburden results that exceeded specifications, and it did not resolve conflicting conclusions about the cause.

    21 CFR 211.192
  3. The company’s visual inspection program lacked defect severity classification and limits for allowed defects.

    21 CFR 211.100(a)
  4. Finished-product release testing lacked adequate identity or assay testing for the active ingredient Hypromellose, and the stability program did not adequately support the expiration date or follow the company’s own procedure.

    21 CFR 211.160(b); 21 CFR 211.166(a)
  5. The company’s quality unit did not adequately oversee manufacturing and external services, and the company had not conducted annual product reviews since 2018 or annual reserve sample exams for the past two years.

    21 CFR 211.22(a) and (d)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with detailed remediation plans, investigations, batch lists, and assessments. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • makers of sterile ophthalmic drugs
  • companies using contract manufacturers or external testing labs
  • quality teams responsible for batch release and investigations

This is a summary. Read the original letter on fda.gov.

Oasis Medical, Inc.'s FDA history

Recalls in the last 12 months

May 20 Class II Oasis Medical, Inc.
Drug
Oasis Tears PF, Preservative-Free Lubricant Eye Drops, 10mL/0.34 Fl OZ Bottle, Sterile, Manufactured for: OASIS Medical, Inc., 514 S. Vermont Ave., Glendora, CA 91741, USA, Made in France, NDC 42126-6400-1.
Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision.

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk